GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (AMEX:AIM) » Definitions » Gross Margin %

AIM ImmunoTech (AIM ImmunoTech) Gross Margin % : 81.54% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. AIM ImmunoTech's Gross Profit for the three months ended in Dec. 2023 was $0.05 Mil. AIM ImmunoTech's Revenue for the three months ended in Dec. 2023 was $0.07 Mil. Therefore, AIM ImmunoTech's Gross Margin % for the quarter that ended in Dec. 2023 was 81.54%.


The historical rank and industry rank for AIM ImmunoTech's Gross Margin % or its related term are showing as below:

AIM' s Gross Margin % Range Over the Past 10 Years
Min: -1104.35   Med: -529.63   Max: 79.21
Current: 79.21


During the past 13 years, the highest Gross Margin % of AIM ImmunoTech was 79.21%. The lowest was -1104.35%. And the median was -529.63%.

AIM's Gross Margin % is ranked better than
73.06% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs AIM: 79.21

AIM ImmunoTech had a gross margin of 81.54% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for AIM ImmunoTech was 0.00% per year.


AIM ImmunoTech Gross Margin % Historical Data

The historical data trend for AIM ImmunoTech's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Gross Margin % Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -537.86 -394.48 -529.63 - 79.21

AIM ImmunoTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 34.78 81.54

Competitive Comparison of AIM ImmunoTech's Gross Margin %

For the Biotechnology subindustry, AIM ImmunoTech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Gross Margin % distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Gross Margin % falls into.



AIM ImmunoTech Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

AIM ImmunoTech's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0.2 / 0.202
=(Revenue - Cost of Goods Sold) / Revenue
=(0.202 - 0.042) / 0.202
=79.21 %

AIM ImmunoTech's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.1 / 0.065
=(Revenue - Cost of Goods Sold) / Revenue
=(0.065 - 0.012) / 0.065
=81.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


AIM ImmunoTech  (AMEX:AIM) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

AIM ImmunoTech had a gross margin of 81.54% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


AIM ImmunoTech Gross Margin % Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (AIM ImmunoTech) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Executives
Thomas K. Equels director, officer: Vice Chairman of Board 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stewart Appelrouth director 2117 SW HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii director 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Ellen M Lintal officer: CFO 2117 SW HWY 484, OCALA FL 34473
William M Mitchell director 2117 SW HWY 484, OCALA FL 34473
Wayne S. Springate officer: VP of Operations 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
David R Strayer other: Medical Director 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale officer: CFO 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli officer: VP, Quality Control 510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander officer: VP of Process/QualityAssurance 784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey officer: Senior Vice President 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii officer: CFO 23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence director 250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli officer: President & COO P.O. BOX 521, NEW VERNON NJ 07976

AIM ImmunoTech (AIM ImmunoTech) Headlines

From GuruFocus